PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β.
Fan, Rui-Fang
PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β. [electronic resource] - Molecular medicine reports Oct 2017 - 4603-4612 p. digital
Publication Type: Journal Article
1791-3004
10.3892/mmr.2017.7215 doi
Antineoplastic Agents--pharmacology
Apoptosis--drug effects
Benzylidene Compounds--pharmacology
Cell Line, Tumor
Cell Proliferation--drug effects
Cell Survival--drug effects
Glycogen Synthase Kinase 3 beta--metabolism
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Protein Kinase Inhibitors--pharmacology
Protein Transport
Proto-Oncogene Proteins c-pim-1--antagonists & inhibitors
Thiazolidinediones--pharmacology
beta Catenin--metabolism
PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β. [electronic resource] - Molecular medicine reports Oct 2017 - 4603-4612 p. digital
Publication Type: Journal Article
1791-3004
10.3892/mmr.2017.7215 doi
Antineoplastic Agents--pharmacology
Apoptosis--drug effects
Benzylidene Compounds--pharmacology
Cell Line, Tumor
Cell Proliferation--drug effects
Cell Survival--drug effects
Glycogen Synthase Kinase 3 beta--metabolism
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Protein Kinase Inhibitors--pharmacology
Protein Transport
Proto-Oncogene Proteins c-pim-1--antagonists & inhibitors
Thiazolidinediones--pharmacology
beta Catenin--metabolism